About Patch
Patch is a Healthcare company based in New York (United States) founded in 2020, and was acquired by Ginkgo Bioworks in February 2024. Gene therapies for a broad range of diseases are developed. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2020 and based in New York, United States, Patch operates in the biotechnology sector. Gene therapies are engineered to address various disease conditions through a platform that incorporates large-scale DNA synthesis and machine learning. This approach supports the creation of targeted treatments for multiple health challenges, with ongoing development focused on scalability and precision in therapeutic applications.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website patch.bio
- Social LinkedIn
- Acquired by Ginkgo Bioworks (Feb 2024)
- Investors
- Acquired byGinkgo Bioworks
(Feb 2024)
Investors in Patch
Patch has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ginkgo Bioworks.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Gene editing-based cultured ingredients are provided for agriculture. | 2008 | ginkgobioworks.com | Boston, United States |
Investor details for Patch
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Patch
1 people are tracked at Patch (1 in team).
| Name | Role | Group |
|---|---|---|
Görkem Garipler | Senior Scientist | Team |
Complete people profiles for Patch
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Patch
2 dated milestones of Patch across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Patch is founded.
- Exit Acquired by Ginkgo Bioworks.
Competitors of Patch
Patch has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Patch
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Patch (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Patch
Complete news archive for Patch
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Patch
Patch was founded in 2020.
Patch is headquartered in New York, United States. It is registered at New York, New York, United States.
Founded in 2020 and based in New York, United States, Patch operates in the biotechnology sector. Gene therapies are engineered to address various disease conditions through a platform that incorporates large-scale DNA synthesis and machine learning. This approach supports the creation of targeted treatments for multiple health challenges, with ongoing development focused on scalability and precision in therapeutic applications.
Patch's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Patch has 1 investor. Key investors include Ginkgo Bioworks.
Yes. Patch was acquired by Ginkgo Bioworks in February 2024.